Weight-Loss Injections Mask Obesity's Real Causes

Scientists are cautioning that the increasing popularity of weight-loss injections, including Wegovy and Ozempic, may divert attention from the genuine causes of rising obesity rates. A new paper published in The Lancet Regional Health Europe, endorsed by over 700 researchers, argues that while these GLP-1 drugs are a significant medical advance, they do not tackle the epidemic's core drivers.

The research highlights that obesity, affecting over one billion people globally, is fueled by poor food environments, urban design that discourages exercise, and growing social inequality. Experts stress that while pharmacological treatments can help individuals, they are not a substitute for structural changes. Without addressing root causes like these, the inflow of new patients will persist.

To achieve lasting health improvements, the paper advocates for increased and sustained investment in obesity prevention. Key policy priorities include stricter food system regulation, promotion of active living environments, and efforts to reduce socioeconomic disparities. Relying solely on long-term drug treatments without addressing underlying issues could also lead to escalating healthcare costs.